Menu
GLOW conducts NLPHL research aimed at optimizing the diagnosis, care, and outcomes for patients of all ages diagnosed with NLPHL worldwide.
Please review the GLOW publication policy below before completing a GLOW project application form. If you are not currently a GLOW researcher and would like to do research with GLOW, please email GLOW@urmc.rochester.edu to discuss our research processes.
GLOW maintains the world’s largest database of clinical data from over 2,000 patients of all ages and stages who have been diagnosed with NLPHL. As of 2022, GLOW is partnering with the Hodgkin Lymphoma Data Collaboration (NODAL) and the Pediatric Cancer Data Commons/Data for the Common Good to harmonize and house incoming retrospective clinical trials data. To learn more about how your site can contribute NLPHL case data to the GLOW retrospective database via NODAL, please contact Suzi Birz (sbirz@bsd.uchicago.edu) or email GLOW@urmc.rochester.edu.
The GLOW NLPHL biobank resides at Stanford University. Researchers who are interested in sharing or utilizing samples for collaborative research with GLOW may contact GLOW@urmc.rochester.edu to discuss.
ID: NCT06098430
Purpose: NLPHLPRO is the first study of patient-reported outcomes in patients diagnosed with NLPHL. This multi-site GLOW study was designed by the GLOW Patient-Reported Outcomes Committee under the leadership of Dr. Ajay Major.
Principal Investigators: Valerie Crabtree (St. Jude Children’s Research Hospital), Anna Jones, (St. Jude Children’s Research Hospital), Ajay Major (University of Colorado School of Medicine), Jamie Flerlage (University of Rochester Medicine), Matthew Rees (St. Jude Children’s Research Hospital)
Study Sites: Dana-Farber Cancer Institute & Harvard University, Hackensack University Medical Center, Memorial Sloan Kettering Cancer Center, Stanford University, St. Jude Children’s Research Hospital, University of Colorado-Denver, University of Rochester Medicine.
Funder(s): St. Jude Children’s Research Hospital, ALSAC
Purpose: The RADIANCE clinical trial will assess whether de-intensified frontline therapy provides non-inferior disease control in patients with low-risk NLPHL (LP-IPS <2).
Principal Investigators: Jamie Flerlage (University of Rochester Medicine), Michael Binkley (Stanford University), Yasodha Natkunam (Stanford University), Oscar Silva (Stanford University), Ajay Major (University of Colorado-Denver)
Study Sites: University of Rochester Medicine, Stanford University, University of Colorado-Denver
Funder(s): Rally Foundation for Childhood Cancer Research
Additional NLPHL clinical trials may be available. Below are organizations that maintain databases of active and historical clinical research.
The Global nLPHL One Working Group is committed to improving outcomes for all patients diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma.
Researchers: Complete our Tell Us About You form or email us
Patients & care partners: Email to join our listserv or become a NLPHL patient advocate
Click here to support NLPHL research